Priti Patel
About Priti Patel
Priti Patel is an experienced oncology leader and consultant CMO at AsherBio, known for her extensive work in clinical trials and cancer therapeutics development across various biotechnology and pharmaceutical companies.
Priti Patel - Consultant CMO at AsherBio
Priti Patel serves as the Interim Consultant Chief Medical Officer at AsherBio. In this role, she oversees the clinical development organization and clinical trials. Priti brings a wealth of experience and a proven track record in developing, evaluating, and advancing cancer therapeutics. Her work involves strategic oversight and execution of clinical initiatives in multiple oncology indications.
Priti Patel's Educational Background
Priti Patel received her B.A. and Masters in Public Health from Johns Hopkins University. She then earned her M.D. from the University of Vermont College of Medicine. Furthering her specialization, Priti completed an internship and residency in internal medicine as well as post-doctoral fellowships in hematology and medical oncology at Stanford University Hospital.
Priti Patel's Experience in Oncology Therapeutics
Priti Patel has comprehensive experience in oncology therapeutics, having led numerous clinical development projects. At Neoelukin Therapeutics, she was responsible for developing NL-201, a first-of-its-kind de novo protein combining IL-2 and IL-15 agonists. At AstraZeneca and Acerta Pharma, she spearheaded the clinical development and trial execution for investigational therapeutics, notably leading over six Phase 3 and twenty Phase 1/2 studies. Her efforts contributed to the global approval of acalabrutinib for chronic lymphocytic leukemia and mantle cell lymphoma.
Priti Patel's Role in Strategic Clinical Development
At Neoelukin Therapeutics, Priti Patel built the clinical development organization and led development efforts for innovative cancer therapies. As the Vice President and Head of Hematology Clinical Development at AstraZeneca, she guided the clinical strategy and trial execution for blood cancers. Her tenure at Onyx Pharmaceuticals focused on strategic clinical development, significantly contributing to the approval of carfilzomib for multiple myeloma.
Priti Patel's Contributions to Scientific Literature
Priti Patel has co-authored numerous scientific papers in peer-reviewed medical journals. Her contributions to the field of oncology are highlighted through her publications, which focus on various aspects of cancer therapeutics and clinical trials. Her work adds significant value to the scientific community and aids in the ongoing advancement of cancer treatments.